|Year : 2011 | Volume
| Issue : 4 | Page : 442-447
Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial
Mohammad Mohammadianpanah1, Sasan Razmjou-Ghalaei2, Amin Shafizad3, Yaghoub Ashouri-Taziani1, Bijan Khademi4, Niloofar Ahmadloo1, Mansour Ansari1, Shapour Omidvari1, Ahmad Mosalaei5, Mohammad Amin Mosleh-Shirazi1
1 Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Radiation Oncology, Golestan Hospital, Ahwaz University of Medical Sciences, Ahwaz, Iran
3 Department of Radiation Oncology, Hormaozgan University of Medical Sciences, Bandar Abbass, Iran
4 Department of Otolaryngology, Head and Neck Surgery, Khalili Hospital and Cancer Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
5 Department of Radiation Oncology, Namazi Hospital and Cancer Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
|Date of Web Publication||19-Jan-2012|
Department of Radiation Oncology, Cancer Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz 71936-11351
Source of Support: Shiraz University of Medical Sciences as research number project 2664, Conflict of Interest: The authors disclose any commercial or other associations that might pose a confl ict of interest in connection with submitted manuscript.
Background: This is the first study that aimed to determine the efficacy and safety of concurrent chemoradiation with weekly cisplatin ± celecoxib 100 mg twice daily in locally advanced undifferentiated nasopharyngeal carcinoma.
Materials and Methods: Eligible patients had newly diagnosed locally advanced (T3-T4, and/or N2-N3, M0) undifferentiated nasopharyngeal carcinoma, no prior therapy, Karnofsky performance status ≥ 70, and normal organ function. The patients were assigned to receive 7 weeks concurrent chemoradiation (70 Gy) with weekly cisplatin 30 mg/m 2 with either celecoxib 100 mg twice daily, (study group, n = 26) or placebo (control group, n = 27) followed by adjuvant combined chemotherapy with cisplatin 70 mg/m 2 on day 1 plus 5-fluorouracil 750 mg/m 2 /d with 8-h infusion on days 1-3, 3-weekly for 3 cycles.
Results: Overall clinical response rate was 100% in both groups. Complete and partial clinical response rates were 64% and 36% in the study group and 44% and 56% in the control group, respectively (P > 0.25). The addition of celecoxib to concurrent chemoradiation was associated with improved 2-year locoregional control rate from 84% to 100% (P = 0.039).
Conclusions: The addition of celecoxib 100 mg twice daily to concurrent chemoradiation improved 2-year locoregional control rate.
Keywords: Celecoxib, chemotherapy, concurrent chemoradiation, cyclooxygenase-2 (COX-2) inhibitors, locally advanced undifferentiated nasopharyngeal carcinoma, weekly cisplatin
|How to cite this article:|
Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, Ansari M, Omidvari S, Mosalaei A, Mosleh-Shirazi MA. Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial. J Can Res Ther 2011;7:442-7
|How to cite this URL:|
Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, Ansari M, Omidvari S, Mosalaei A, Mosleh-Shirazi MA. Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial. J Can Res Ther [serial online] 2011 [cited 2020 Jun 4];7:442-7. Available from: http://www.cancerjournal.net/text.asp?2011/7/4/442/92013
| > Introduction|| |
Nasopharyngeal carcinoma has unique features of epidemiology, staging, and treatment compared to other cancers of the head and neck. The majority of patients with nasopharyngeal carcinoma present at locally advanced stage. Radiation therapy (RT) alone or combined chemoradiation is the current cornerstone in the management of nasopharyngeal carcinoma. , The poor prognosis of locally advanced disease has led to increasing interests in exploring the use of novel antineoplastic agents in these patients. Cyclooxygenase-2 (COX-2) is one interesting potential target for the treatment of nasopharyngeal carcinoma. COX-2 enzyme overexpresses in many malignant tumors, as well as nasopharyngeal carcinoma and is associated with more aggressive tumor behavior and poor prognosis. Several preclinical studies on selective COX-2 inhibitors, such as celecoxib, have shown that these agents have antitumor, antiangiogenesis, and radiosensitizing effects. ,,,,,,,,,,, In addition, there are evidences that COX-2 inhibitors have been associated with significant reduction in vascular permeability and decrease in acute and chronic inflammation. 
Celecoxib has been progressively used in clinical studies for improving the response to therapy in many cancers. ,,,, This is the first study that aimed to determine the efficacy and safety of concurrent chemoradiation with weekly cisplatin ± celecoxib 100 mg twice daily in locally advanced undifferentiated nasopharyngeal carcinoma.
| > Materials and Methods|| |
This phase II-III study enrolled patients with newly diagnosed locally advanced (T3-T4 and/or N2-N3, M0) undifferentiated nasopharyngeal carcinoma. From January 2007 to November 2008, 53 patients with locally advanced undifferentiated nasopharyngeal carcinoma were randomly assigned to concurrent chemoradiation with weekly cisplatin (30 mg/m 2 ) plus either celecoxib 100 mg twice daily (study group, n = 26) or placebo (control group, n = 27). The trial was approved by the local university ethics committee in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. All the patients provided written informed consent prior to their inclusion in the study. The diagnosis of the disease was based on nasopharyngeal biopsy and a histopathologic examination of the specimen. Eligible patients had to be aged 15-80 years, Karnofsky performance score of ≥70 and have biopsy-proven, newly diagnosed locally advanced undifferentiated nasopharyngeal carcinoma and with normal or acceptable kidney, liver, cardiovascular, and bone marrow functions. Exclusion criteria included prior treatment for nasopharyngeal carcinoma, clinical and imaging evidence of distant metastasis before or during the trial, inability to receive celecoxib or chemotherapy for any reason, presence of severe cardiovascular, kidney, liver, inflammatory bowel disease, or coagulation disorders, and patients' refusal to participate in the trial or to sign on the consent form.
All the patients were initially treated with concurrent chemoradiation with weekly cisplatin (30 mg/m 2 ) from the first day of RT, up to 7 cycles. They received a total dose of 70 Gy with 2 Gy daily fractions in 7 weeks with conventional external beam RT using megavoltage telecobalt units or linear accelerator photons. The primary site and upper cervical lymph nodes were treated with two lateral parallel opposed fields; the lower cervical lymph nodes were treated with a separate en face anterior field with a central block. The spinal cord was excluded from the radiation fields after 44 Gy. After 50 Gy, RT was continued to the primary tumor, using reduced size fields, up to 70 Gy. The dose was calculated at the central axis of the upper field. Metastatic cervical lymph nodes were boosted through a direct electron field or anterior and posterior neck fields with a central block and a dose of 15-20 Gy. Three patients were excluded due to early skeletal metastasis (2 patients) or chemotherapy refusal (1 patient), during the course of concurrent chemoradiation. After completion of concurrent chemoradiation, all the patients received adjuvant chemotherapy in an outpatient setting, consisting of cisplatin 70 mg/m 2 for day 1, and 5-fluorouracil (5-FU) 750 mg/m 2 /day with 8-h infusion on days 1-3, which was repeated every 3 weeks, up to 3 cycles. Antiemetic medication including a selective 5-hydroxytryptamine-3 (5HT3) antagonist and steroids was routinely prescribed intravenously for all chemotherapy cycles. The patients in the study group received celecoxib 100 mg twice a day from the first day of concurrent chemoradiation until 3 weeks after the last cycle of adjuvant chemotherapy (18th week). The patients in the control group received placebo with the same schedule as the study group [Figure 1]. Clinical response rates and safety were the primary and secondary endpoints, respectively.
Before starting therapy, all the patients were asked about any history of allergic reaction to nonsteroidal anti-inflammatory drugs, celecoxib intolerance, uncontrolled hypertension, gastrointestinal bleeding, gastrointestinal ulcer, hepatic and/or renal dysfunction, and/or insufficiency. All the patients were examined with special attention on the status of the cervical lymph nodes regarding the location of the involved nodes, and their sizes, consistency, and fixation. Location, size, and extension of the primary tumor and the cervical lymph nodes were assessed by magnetic resonance imaging (MRI) and computed tomography (CT) scans. Stages were assigned according to the 6 th edition of the American Joint Committee on Cancer (AJCC) TNM 2002 staging system. The patients' functional statuses were evaluated according to the Karnofsky performance status. Chest radiograph and laboratory tests, including complete blood count (CBC), erythrocyte sedimentation rate (ESR), lactic dehydrogenase (LDH), liver function tests (LFT), and renal function tests (RFT) were obtained from all the patients. A whole body bone scintigraphy was performed in symptomatic patients or those with elevated alkaline phosphatase level. After completion of concurrent chemoradiation, all the patients from both groups were followed and evaluated during the rest of the treatment every 3 weeks before every adjuvant chemotherapy administration. At the end of intervention (18th week), new evaluation, including CBC, ESR, LDH, LFT, RFT, and MRI and CT scan of the primary site and neck were performed for all the patients.
The patients were followed weekly during the first 7 weeks of treatment, before every concurrent cisplatin infusion. They were examined every week and the changes of their lymph nodes and Karnofsky performance statuses were evaluated. Grades of mucositis and dermatitis were determined based on the Radiation Therapy Oncology Group (RTOG) scoring criteria. CBC, ESR, LDH, LFT, and RFT were checked weekly. The grades of the hematologic toxicities were also determined based on the RTOG scoring criteria. Complete response was defined as complete (100%) clinical and radiologic disappearance of the tumor. Partial response was defined as incomplete (less than 100% but more than 50%) clinical and radiologic shrinkage of the tumor. Less than 50% clinical and radiologic shrinkage of the tumor was considered as no response. Assessment of clinical response rates was performed 18 weeks following the first day of RT.
A minimum sample size required 24 patients in each arm to ensure 80% power at the 5% significance level for detecting a 40% improvement in the clinical complete response rate from 30% to 70%. The survival durations were calculated from the date of RT start till the events of treatment failure (locoregional control), death from any reason (overall survival) or the last follow-up. The significance of differences in survival was evaluated using the log-rank test. The Chi-squared (χ2 ) test, Fisher's exact test, and Mann-Whitney test were used for comparing the clinical response rates and the clinicopathologic characteristics of the groups. Analysis for disease-free survival and overall survival rates was performed using the Kaplan-Meier method, and prognostic factors were compared using the log-rank test. P values less than 0.05 were considered significant.
| > Results|| |
After excluding 3 patients who developed skeletal metastases or refused chemotherapy, 50 patients were evaluable (25 patients in each group). The mean age was 42 years (range 18-69 years) in the study group, and 44 years (range 18-65 years) in the control group. In each group, 15 patients (60%) were men and 10 (40%) were women. Thirty-five patients (70%) presented with stage III disease and 30% had stage IV disease. The median dose of radiation was 70 Gy (range 60-70 Gy) in both groups. In addition all the patients received a median 5 cycles of weekly cisplatin (range 4-7 cycles); and a median 3 cycles of adjuvant chemotherapy (range 2-3 cycles) [Table 1].
|Table 1: Patients and treatment characteristics for all 50 patients with locally advanced undifferentiated nasopharyngeal carcinoma|
Click here to view
Overall clinical response rate was 100% in both groups. Complete and partial clinical response rates were 64% and 36% in the study group, and 44% and 56% in the control group, respectively (P > 0.25).
Patients with partial response had suspected (7 in study group and 10 in control group) or obvious (2 in study group and 4 in control group) residual disease at primary site on imaging. Those with obvious residual disease underwent direct nasopharyngoscopy for accurate clinical evaluation and pathologic confirmation. Among these patients, pathologic examination revealed viable residual disease in 2 patients of the control group, and only necrosis and inflammation in the remaining 4 patients. For patients with partial response and suspected residual disease, a follow-up imaging (MRI and CT scan) was performed 3 months later. All of the 17 patients had normal follow-up imaging without evidence of abnormal finding that favors residual disease. Therefore, when considering these results, the ultimate complete response rates were increased from 64% to 100% in the study group, and from 44% to 92% in the control group at the end of the 30 th week. During the follow-up period 12 patients experienced recurrent disease (8 cases with isolated skeletal relapse and 4 cases with locoregional and skeletal failure). After a median follow-up of 26 months (range 21-31 months) for surviving patients, 38 patients are alive and without disease, 5 (2 of the study group and 3 of the control group) are alive with disease and 7 (3 of the study group and 4 of the control group) died due to disease. We found a significant improvement in 2-year locoregional control rate in the study group when compared with the control group (100% vs. 84%, P = 0.039). However, 2-year overall survival was not significantly different by treatment groups (88% vs. 84%, P = 0.698). In addition, there was no significant association between the stage of disease and complete response rate (P > 0.15).
All the patients well tolerated concurrent chemoradiation and adjuvant combined chemotherapy regimen. Acute treatment-related toxicities were manageable in both the groups. The patients in study group tolerated celecoxib well, and none of them had significant complaint of side effects. Anorexia, nausea, pharyngitis, fatigue, vomiting, xerostomia, and dermatitis were the most frequent treatment-related toxicities in both groups. None of patients developed grade 4 toxicities, and treatment-related death was not observed. One patient in the study group developed profound hypokalemia (2.1 mmol/L) 2 weeks after the third cycles of adjuvant chemotherapy (17th weeks). Another patient in the study group developed lung abscess 4 weeks after the third cycles of adjuvant chemotherapy (19th weeks). All the patients in both the groups were managed well, with a similar rate of late sequelae. Xerostomia, soft tissue fibrosis, otitis media, dental caries, and hearing loss were the most frequent late complications in both arms [Figure 2]. There was no significant difference in terms of acute treatment-related toxicities between the 2 groups. [Table 2] shows the frequency of acute treatment-related toxicity rates of the 2 groups.
|Figure 2: Relative late complication frequency in the study and control arm|
Click here to view
|Table 2: Acute toxicity of concurrent chemoradiation and adjuvant chemotherapy in 50 patients with locally advanced undifferentiated nasopharyngeal carcinoma|
Click here to view
| > Discussion|| |
There are increasing evidences of the superiority of concurrent chemoradiation compared to radiotherapy alone in patients with locally advanced nasopharyngeal carcinoma. According to these evidences, concurrent chemoradiation with cisplatin-based regimen with or without neoadjuvant or adjuvant chemotherapy is currently considered the standard of care for locoregionally advanced nasopharyngeal carcinoma. Despite this improvement, outcome of patients with locally advanced nasopharyngeal carcinoma remains poor. [1,2] Therefore, novel antineoplastic agents need to receive more attention. One of the most promising agents is COX-2 inhibitors, which are under investigation for improving the response to radiotherapy and chemotherapy. COX-2 inhibitors, such as celecoxib, may have a role in the treatment of cancers via inhibiting cellular proliferation and angiogenesis, decreasing distant metastases, and inducing apoptosis. ,,,,,,,,,,,
COX-2 enzyme overexpresses in many different tumors, and its role in tumorigenesis, angiogenesis, transformation, and metastasis has been shown in several studies. ,,,,,,,,,,, Many studies assessed the prophylactic role of COX-2 inhibitors in various tumors, such as colon and breast cancer, and showed that nonsteroidal anti-inflammatory drugs and COX-2 inhibitors decrease the incidence of colon and breast cancer via inhibiting cyclooxygenase-1 and -2 enzymes. , Lee et al. showed that COX-2 enzyme was overexpressed in cultured cells of squamous cell carcinoma of the head and neck, when compared with normal cells. The authors concluded that COX-2 inhibitors significantly decreased cell growth and increased apoptosis in cultured cells.  This study and several others have shown that COX-2 inhibitors may have chemopreventive and therapeutic effects in squamous cell carcinoma of the head and neck. ,,,, In another study, Soo et al. found celecoxib 400 mg twice daily for 14 days reduced microvessel density and induced changes in gene expression in patients with newly diagnosed, untreated nasopharyngeal carcinoma. 
In addition, several studies found that COX-2 inhibitors significantly enhanced the response of tumor cells to radiotherapy. The exact mechanism(s) responsible for the antiproliferative effect of COX-2 inhibitors remains to be defined; however, antiangiogenic effects of COX-2 inhibitors seem to be mainly responsible for increasing the antitumor effects of ionizing radiation.  Therefore, COX-2 inhibitors have a potential role for improving response to radiotherapy. ,,,,
Several clinical trials studied the role of COX-2 inhibitors in improving response to radiotherapy or chemotherapy in many different cancers, such as head and neck and breast cancer. Despite promising results in preclinical studies, most clinical studies showed that COX-2 inhibitors have had no effect on response or survival rates in patients. ,,,,,,, In a phase I-II trial at Princess Margaret Hospital, the toxicity and efficacy of celecoxib in combination with definitive chemoradiation were evaluated in 31 women with locally advanced cervical cancer. All the patients received oral celecoxib 400 mg twice daily for 2 weeks before and during chemoradiation. They found acute grade 3/4 hematologic and gastrointestinal toxicities were the most frequent and were largely attributed to chemotherapy. Twenty-five of 31 patients (81%) achieved complete response during the first year of follow-up. The authors concluded that definitive chemoradiation in combination with celecoxib was associated with acceptable acute toxicity, and higher than expected late complications. They found the addition of celecoxib to definitive chemoradiation did not improve tumor response. 
Another phase II trial studied response rate, toxicity, and overall survival rates in patients with potentially resectable esophageal cancer. Thirty-one patients received neoadjuvant chemoradiation with cisplatin and 5-FU plus celecoxib 200 mg twice daily on day 1 until surgery and then at 400 mg twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years. The patients underwent esophagectomy 4-6 weeks after completion of chemoradiation. Most patients experienced grade 3/4 toxicities, of which diarrhea, neutropenia, nausea/vomiting, esophagitis, dehydration, and stomatitis were most frequent. There were 7 treatment-related deaths.  Of 22 patients who underwent esophagectomy, 5 had pathologic complete response (22%). The authors concluded that the addition of celecoxib 400 mg twice daily to chemoradiation was well tolerated, however, the pathologic complete response rate of 22% in their study was similar to that reported with the use of preoperative chemoradiation alone in other trials. 
Recently, few studies evaluated the efficacy and safety of concurrent chemoradiation with weekly cisplatin in patients with nasopharyngeal carcinoma. These studies concluded that this treatment approach is safe and effective for most patients with nasopharyngeal carcinoma even in the elderly patients. ,,,
The present study is the first clinical trial evaluating the efficacy and safety of low-dose (100 mg twice daily) celecoxib with concurrent chemoradiation plus weekly cisplatin in locally advanced undifferentiated nasopharyngeal carcinoma. Consistent with the recent studies, this study confirmed the safety and efficacy of this treatment for patients with locally advanced undifferentiated nasopharyngeal carcinoma. ,,, The addition of celecoxib 100 mg twice daily did not change the rates of overall survival or treatment-related acute toxicities, however, it significantly improved locoregional control rate, which is a promising point that should be evaluated in future studies using higher doses of celecoxib. The incidence of severe treatment-related toxicities was infrequent and most patients well tolerated the treatment. In this study, 1 patient developed severe hypokalemia, a complication of cisplatin-based chemotherapy that was rarely reported in the literature.  The rather high incidence of skeletal metastases in this study may be attributable to the suboptimal or ineffective adjuvant systemic chemotherapy and/or aggressive behavior of this neoplasm. In any case, this highly suggests the need for a more effective systemic treatment in these patients. The use of more effective chemotherapeutic agents, such as taxane-containing regimen, particularly in neoadjuvant setting, may further improve locoregional control and survival in patients with locally advanced undifferentiated nasopharyngeal carcinoma. ,
There is no evidence in phase I or phase II clinical trials defining radiosensitizing dose for celecoxib. In recent few phase I clinical trials an escalating dose (100-400 mg, twice daily) has been used. , The rationale for this lower dose administration of celecoxib was to evaluate the radiosensitizing effect of lower dose of celecoxib, rather than antitumor and antiangiogenesis effects. Most other studies, however, despite using higher doses of celecoxib, failed to show any survival benefit for the addition of celecoxib. ,,
| > Conclusions|| |
Concurrent chemoradiation with weekly cisplatin followed by adjuvant combined cisplatin-based chemotherapy is highly effective in locally advanced undifferentiated nasopharyngeal carcinoma. The addition of celecoxib 100 mg twice daily to concurrent chemoradiation improved 2-year locoregional control rate, however, its effect on the response rates, treatment-related toxicities and overall survival was not statistically significant.
| > Acknowledgment|| |
This clinical trial was approved and supported by Shiraz University of Medical Sciences as research number project 2664. In addition, the study was registered on the clinical trials registration website of Australia and New Zealand (ANZCTR) on 12 October 2008 (number: ACTRN12608000449336).
| > References|| |
|1.||Agulnik M, Siu LL. State-of-the-art management of nasopharyngeal carcinoma: Current and future directions. Br J Cancer 2005;92:799-806. |
|2.||Afqir S, Ismaili N, Errihani H. Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: Current status. J Cancer Res Ther 2009;5:3-7. |
|3.||Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-81. |
|4.||Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005;11:1618-28. |
|5.||Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res 2002;22:2089-96. |
|6.||Soo RA, Wu J, Aggarwal A, Tao Q, Hsieh W, Putti T, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol 2006;17:1625-30. |
|7.||Lim SC, Park SY, Do NY. Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep 2003;10:1073-9. |
|8.||Chen PY, Long QC. Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta Pharmacol Sin 2004;25:943-9. |
|9.||Ye F, Wu J, Dunn T, Yi J, Tong X, Zhang D. Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein. Cancer Lett 2004;211:39-46. |
|10.||Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy. Am J Clin Oncol 2003;26:S66-9. |
|11.||Davis TW, Hunter N, Trifan OC, Milas L, Masferrer JL. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol 2003;26:S58-61. |
|12.||Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J Natl Cancer Inst 2003;95:1440-52. |
|13.||Raju U, Ariga H, Dittmann K, Nakata E, Ang KK, Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 2005;63:520-8. |
|14.||Milas L, Mason KA, Crane CH, Liao Z, Masferrer J. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Wilson Park) 2003;17:15-24. |
|15.||Süleyman H, Demircan B, Karagöz Y, Oztaºan N, Süleyman B. Anti-inflammatory effects of selective COX-2 inhibitors. Pol J Pharmacol 2004;56:775-80. |
|16.||Herrera FG, Chan P, Doll C, Milosevic M, Oza A, Syed A, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys 2007;67:97-103. |
|17.||Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K, et al. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: Preliminary results. Oncology (Wilson Park) 2004;18:18-21. |
|18.||Tfayli A, Yang J, Kojouri1 K, Kesserwan C, Jafari M, Ozer H. Neoadjuvant therapy with celecoxib to women with early stage breast cancer. Neoplasma 2008;55:122-6. |
|19.||Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 2008;26:53-9. |
|20.||Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111:13-7. |
|21.||Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D'Cruz AK, Dinshaw KA. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: A single-institution experience. Head Neck Oncol 2009;1:17. |
|22.||Isobe K, Uno T, Aruga T, Kawakami H, Ueno N, Hanazawa T, et al. Weekly cisplatin administration concurrent with radiation therapy for locoregionally advanced nasopharyngeal carcinoma. Int J Clin Oncol 2005;10:201-3. |
|23.||Park JH, Nam SY, Lee SW, Kim SB, Kim SY, Lee BJ, et al. Radiation therapy with UFT and low dose weekly cisplatin for nasopharyngeal carcinoma. Auris Nasus Larynx 2005;32:43-8. |
|24.||Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27:242-9. |
|25.||Mohammadianpanah M, Omidvari S, Mosalaei A, Ahmadloo N. Cisplatin-induced hypokalemic paralysis. Clin Ther 2004;26:1320-3. |
|26.||Bae WK, Hwang JE, Shim HJ, Cho SH, Lee JK, Lim SC, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol 2010;65:589-95. |
|27.||Kao J, Genden EM, Chen CT, Rivera M, Tong CC, Misiukiewicz K, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011;117:3173-81. |
|28.||Rich TA, Shepard R. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: Esophagus, stomach, and pancreas. Am J Clin Oncol 2003;26:S110-3. |
|29.||Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009;15:2158-65. |
|30.||Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, et al. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys 2007;69:111-7. |
|31.||Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 2008;10:300-8. |
[Figure 1], [Figure 2]
[Table 1], [Table 2]
|This article has been cited by|
||Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy
| ||E.J. Searle,T.M. Illidge,I.J. Stratford |
| ||Clinical Oncology. 2014; 26(5): 266 |
|[Pubmed] | [DOI]|
||COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib : A quantitative immunohistochemical analysis of RTOG C0128
| ||Doll, C.M. and Winter, K. and Gaffney, D.K. and Ryu, J.K. and Jhingran, A. and Dicker, A.P. and Weidhaas, J.B. and Miller, B.E. and Magliocco, A.M. |
| ||International Journal of Gynecological Cancer. 2013; 23(1): 176-183 |
||Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: A meta-analysis
| ||Wei Sun,Guoxian Long,Junfeng Wang,Qi Mei,Dongbo Liu,Guoqing Hu,David W. Eisele |
| ||Head & Neck. 2013; : n/a |
|[Pubmed] | [DOI]|
||COX-2 Expression and Survival in Patients With Locally Advanced Cervical Cancer Treated With Chemoradiotherapy and Celecoxib
| ||Corinne M. Doll,Kathryn Winter,David K. Gaffney,Janice K. Ryu,Anuja Jhingran,Adam P. Dicker,Joanne B. Weidhaas,Brigitte E. Miller,Anthony M. Magliocco |
| ||International Journal of Gynecological Cancer. 2013; 23(1): 176 |
|[Pubmed] | [DOI]|
||Three concerns with regards to the utilization of COX-2 inhibitor (celecoxib) in combination with standard chemoradiotherapy for nasopharyngeal carcinoma
| ||Revannasiddaiah, S. and Gupta, M. and Seam, R. and Rastogi, M. |
| ||Journal of Cancer Research and Therapeutics. 2012; 8(3): 464-465 |